Abstract 511: A small molecule CET019 inhibits progression of triple negative breast cancer

Abstract Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer, which accounts for 15-20% of total diagnosed breast cancer cases with high rates of metastasis and recurrence. Metastatic breast cancer remains one of the leading causes of cancer related mortality in women. The majority of women with this disease relapse after curative-intent therapy for early breast cancer; while a smaller proportion present with distant metastases at initial diagnosis. Our efforts of developing effective therapies for TNBC have identified CET019, a novel small molecule that effectively inhibits the growth of breast cancer cells. We found that CET019 impedes the clonogenic potential and growth of triple-negative breast cancer cells (MDA-MB-231, MDA-MB-468, SUM159 and 4T1). CET019 treatment induces the G2/M phase cell cycle arrest in TNBC cells. Moreover, the mouse xenograft study with different TNBC models, found that CET019 inhibits growth and progression compared to vehicle control group. Metastatic nodules in the lungs were inhibited by CET019 compared to control group. Collectively, our in vitro and in vivo experiments, provide foundation to further develop CET019 as a potential drug candidate to treat patients with TNBCs. Citation Format: Arpit Dheeraj, Dhanir Tailor, Fernando Jose Marques, Benedikt Grau, Abel Bermudez, Sharon Pitteri, Sanjay Malhotra. A small molecule CET019 inhibits progression of triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 511.